Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News BiomX Inc PHGE

Healthcare Biotechnology
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic... see more

Current News (NYSEAM:PHGE)

BiomX Announces $3.0 Million Private Placement

GlobeNewswire December 29, 2025

BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review

GlobeNewswire December 8, 2025

BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis

GlobeNewswire November 25, 2025

BiomX Inc. Announces 1-for-19 Reverse Stock Split

GlobeNewswire November 14, 2025

BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates

GlobeNewswire November 12, 2025

BiomX to Report Third Quarter 2025 Financial Results and Program Updates on November 12, 2025

GlobeNewswire November 5, 2025

BiomX Announces Positive FDA Feedback Supporting Next-Generation Phage Cocktail Program for Diabetic Foot Infections

GlobeNewswire November 4, 2025

BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways

GlobeNewswire October 17, 2025

BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire September 4, 2025
View More News ››

Opinion & Analysis (NYSEAM:PHGE)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NYSEAM:PHGE)

BiomX Inc. (NASDAQ:PHGE): Expanding Phage Therapy Pipeline H

http://beyondspx.com/2024/08/02/biomx-inc-nasdaqphge-expanding-phage-therapy-pipeline-holds-promise/
MikeTester - August 3, 2024
View more Bullboard ››

JZR Gold Inc.

JZR Gold Inc.

JZR Gold Inc., a junior mining resource company, engages in the acquisition, exploration, and development of mineral ...
View More »

Podcasts